Black race is an adverse prognostic factor for prostate cancer recurrence following radical prostatectomy in an equal access health care setting.

Abstract

The poorer recurrence-free outcome for black patients even after multivariate adjustment suggests a potentially more aggressive variant of prostate cancer in this population, the etiology of which is unknown. Race should be a stratification factor in clinical trials, especially those including radical prostatectomy and using recurrence-free outcome as an end point.